anti-HPV TCR, pMSGV1(TCR-L053)
The vector of anti-HPV T cell receptor (TCR) is constructed for the engineering of T cell to target HPV. The T cells are genetically modified through transduction with a retroviral vector expressing HPV-specific T cell receptor. And the vector product was designed for the treatment of cancer, HPV 16 infection, or HPV-positive premalignancy.
Cancer, HPV 16 infection, or HPV-positive premalignancy
Murinized (from Human)
Human papillomavirus; HPV; TCR; T cell receptor; transgenic TCR; antigen-specific T cell receptors; Engineering T-cell receptors; recombinant t cell receptors; specific t cell receptor; modified t cell receptor; retroviral vector; Cancer; HPV 16 infection; HPV-positive premalignancy
Human papillomavirus (HPV) is a DNA virus from the papillomavirus family that is capable of infecting humans. Like all papillomaviruses, HPVs establish productive infections only in keratinocytes of the skin or mucous membranes. Most HPV infections are subclinical and will cause no physical symptoms; however, in some people subclinical infections will become clinical and may cause benign papillomas (such as warts [verrucae] or squamous cell papilloma), premalignant lesions that will drive to cancers of the cervix, vulva, vagina, penis, oropharynx and anus. In particular, HPV16 and HPV18 are known to cause around 70% of cervical cancer cases.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.